Obesity Drugs: Access Shift
- Patients are struggling with access as insurers tighten coverage and CVS Caremark dropped Eli Lilly's Zepbound from plans. - Separately, the FDA approved oral Wegovy for chronic weight management based on positive phase III OASIS 4 results. - The market is moving from production shortages to payer and reimbursement constraints, complicating access despite new oral options (npr.org) (appliedclinicaltrialsonline.com) (reuters.com).
The bottleneck in obesity drugs has shifted from factory output to insurance coverage, leaving many patients with fewer covered options even as a pill version arrives. (wusf.org) CVS Caremark said Zepbound was removed from its Standard Control, Advanced Control and Value formularies effective July 1, 2025, while Wegovy remained a preferred option. CVS Caremark says the strategy uses competition and negotiated discounts to lower net costs for clients. (business.caremark.com) Patients in the NPR-reported cases described switching drugs, filing appeals, or stopping treatment after employers or pharmacy benefit managers changed coverage. One patient interviewed after a switch to Wegovy then lost that coverage too when her employer dropped the drug in October. (tspr.org) These medicines work by mimicking a gut hormone called glucagon-like peptide-1, or GLP-1, which helps regulate appetite and blood sugar. For much of 2023 and 2024, the main problem was getting supply; by 2026, large buyers are using formularies and prior authorization rules to decide who gets which brand paid for. (business.caremark.com) Novo Nordisk added a new option in late 2025 when the Food and Drug Administration approved Wegovy tablets for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. The approval letter also covers reducing major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. (accessdata.fda.gov) The pill approval was based on the phase 3 OASIS 4 study, a 64-week trial in 307 adults without diabetes. Applied Clinical Trials and Novo Nordisk said the once-daily 25 milligram tablet showed substantial weight loss and improvements in cardiometabolic measures, with a full U.S. launch planned for January 2026. (appliedclinicaltrialsonline.com) (prnewswire.com) The label shows the tablet was studied in a smaller safety trial of 204 adults treated for up to 64 weeks, and it carries the same class warnings familiar from injectable semaglutide. That means the new format changes how the drug is taken, not the basic safety tradeoffs insurers and patients already weigh. (accessdata.fda.gov) Novo is also still expanding oral semaglutide in diabetes. On April 23, 2026, the company said a phase 3a trial in 132 patients ages 10 to 17 with type 2 diabetes met its main goal on blood-sugar reduction after 26 weeks. (kommunikasjon.ntb.no) (wncy.com) The commercial fight has become as important as the clinical one. A market that spent two years talking about shortages is now sorting patients by formulary status, employer benefit design and exception paperwork, even with a new oral Wegovy on pharmacy shelves. (wusf.org) (business.caremark.com)
